Table 2 Characteristics of patients who... | American Society of Hematology

Table 2

Characteristics of patients who evolved while on eltrombopag

Patient #	Age (y)	Response	Baseline	At evolution	Time on eltrombopag (mo)	Dysplasia	Outcome	Time posttransplant (mo)
7	60	NR	46XY[20]	−7[20]	3	N	Died of progressive cytopenias	N/A
8	18	NR	46XX[6]	+8[9]/46XX[11]	3	N	Transplanted successfully	31
19	20	NR	46XY[20]	−7[5]t(1;16) [3]/46XY[12]	3	N	Transplanted successfully	18
26	67	R	46XY[20]	del(13)[19]/46XY[1]	13	Mild dyserythropoeisis	Transplanted	8
31	41	NR	46XY[20]	+21[3]/46XY[17] −7[2]/46XY[19]	3 6	Mild dyserythropoeisis	Awaiting transplant	N/A
32	66	R	46XY[20]	46XYdel13q[2]/46XY[18]	9	N	Under observation	N/A
36	23	NR	46XY[20]	−7[5],XY[15]	3	N	Transplanted successfully	3
42	17	NR	No metaphases	+1,der(1;7) [4]/46XY[16]	3	N	Transplanted successfully	4

Patient #	Age (y)	Response	Baseline	At evolution	Time on eltrombopag (mo)	Dysplasia	Outcome	Time posttransplant (mo)
7	60	NR	46XY[20]	−7[20]	3	N	Died of progressive cytopenias	N/A
8	18	NR	46XX[6]	+8[9]/46XX[11]	3	N	Transplanted successfully	31
19	20	NR	46XY[20]	−7[5]t(1;16) [3]/46XY[12]	3	N	Transplanted successfully	18
26	67	R	46XY[20]	del(13)[19]/46XY[1]	13	Mild dyserythropoeisis	Transplanted	8
31	41	NR	46XY[20]	+21[3]/46XY[17] −7[2]/46XY[19]	3 6	Mild dyserythropoeisis	Awaiting transplant	N/A
32	66	R	46XY[20]	46XYdel13q[2]/46XY[18]	9	N	Under observation	N/A
36	23	NR	46XY[20]	−7[5],XY[15]	3	N	Transplanted successfully	3
42	17	NR	No metaphases	+1,der(1;7) [4]/46XY[16]	3	N	Transplanted successfully	4

N/A, not applicable; NR, nonresponder; R, responder.